Quantcast

HemCon Signs Licensing Agreement With IT/Sligo

September 1, 2008

HemCon Medical Technologies, a global developer of advanced medical products, has signed an agreement with Institute of Technology Sligo, Ireland, to license the exclusive global rights to research, develop, manufacture and market a controlled release hydrogen peroxide technology that provides broad spectrum antibacterial and antiseptic properties.

This proprietary platform technology provides a full range of product solutions for the wound care, oral care and personal care markets ranging from antimicrobial professional products to personal hygiene solutions for consumers.

The technology allows entry into major new market opportunities for HemCon Medical Technologies. Of particular significance the technology has shown good potential in early studies for the treatment of fungal nail infection.

The agreement is said to allow HemCon to directly commercialize or sub-license these technologies to key medical device and pharmaceutical partners globally.

John Morgan, CEO of HemCon, said: “The new licensing agreement with Institute of Technology Sligo, Ireland (IT/Sligo) is an exciting partnership for HemCon as we continue to grow and pioneer new products in wound care and healing. This particular technology will also expand our presence in key markets like fungal care.”




comments powered by Disqus